Clinical Trial Update: A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED) [Phase 1]

View source ↗

Summary

This is a Phase 1 study evaluating once-weekly doses of odanacatib (MK0822) in healthy adult females. The trial, sponsored by Merck Sharp & Dohme LLC, is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis | Phase 1 | Status: COMPLETED